US FDA rejects Lilly's pancreatic insufficiency enzyme therapy
This article was originally published in Scrip
Executive Summary
Unsurprisingly, Alnara Pharmaceuticals and its parent company Lilly failed to gain US approval for their non-porcine pancreatic enzyme replacement therapy (PERT) liprotamase as a treatment for exocrine pancreatic insufficiency (EPI), a condition in which the body is unable to properly digest fat, protein and carbohydrates and absorb nutrients.